NICE approves anti-inflammatory drug Tildrakizumab for treatment of adult patients with moderate to severe plaque psoriasis

recently,(http:// acompany atPharmaceuticals(http://) in Spain, announced that the National Institute for Health and Clinical Optimization (NICE) had approved the anti-inflammatory drug Ilumezumab as an cost-effective treatment option for the NHS to treat patients with moderate to severe plaque psoriasis suitable for systemic therapyIn the EU, Ilumetri was approved in September 2018 and is currently listed in Germany and will continue to be listed in all EU member statesIlumetri will provide patients with a simple treatment plan, after the completion of the first treatment of the 0th and 4th weeks, the follow-up maintenance treatment period, only every 3 months underthe subcutaneous injection, that is, only 4 times a year, will provide patients with greater convenience, achieve better disease control, improve treatment satisfactionthe activedrug(http://ingredient about IlumetriIlumetri is tildrakizumab, a humanized monoclonal antibody that selectively, high affinity binds to IL-23's p19 subunit, inhibits its results with IL-23 receptors, thereby inhibiting the release of pro-inflammatory cytokines and prosthesis factorsIn the U.Smarket, tildrakizumab was approved in March 2018 and is listed under the brand name Ilumya (tildrakizumab-asmn) for use in adult patients with moderate to severe plaque psoriasis suitable for system therapy or phototherapyIlumetri's approval is based on data from two key Phase III clinical studies (reSURFACE-1, reSURFACE-2)Both studies were randomized, placebo-controlled, multicenter clinical studies with more than 1,800 cases in the group and were conducted in more than 200 clinical
trial (http:// institutions worldwide The main endpoints of the study were that at the 12th week of treatment, the Ilumetri treatment group achieved a 75% skin removal rate (psoriasis area sensitivity index or PASI75) and a physician's overall assessment scale (PGA) score of 0 (clear) or 1 (minimum) for patients compared to the placebo group 　　Data show that in the 12th week of treatment, an average of 63% of patients in the Ilumetri treatment group achieved PASI75 remission, 78% of patients reached PASI75 remission in week 28, and 59% of patients reached PASI90 and 30% of patients reached PASI100 More than 92% of patients who achieved remission during the 28-week treatment period were able to maintain PASI75 remission after one year